| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vitro |
3,4-dihydroxybenzylamine hydrobromide (1 μM–10 mM; 48 hours) suppresses the development of all cell lines with an IC50 of 100 μM for all melanoma cell lines and 122 μM for the SK-MELB cell line. For human SK-MEL-30, SK-MEL-2, SK-MEL-3, and RPMI-7951 cells, the corresponding IC50 values were 30, 84, 90, and 68 μM. Against S91A, S91B, L1210, and SCC-25 cells, its IC50 values are 10, 25, 67, and 184 μM, respectively[2]. SK-MEL-2 and SK-MEL-28 cell lines can be treated with butthionine sulfinyl enhanced with imine (BSO) to increase the cytotoxicity of 3,4-dihydroxybenzylamine hydrobromide (1 μM–10 mM; 48 hours). Marginal pigment cells were made more susceptible to the effects of 3,4-DHBA by BSO treatment, which also decreased the compound's IC50 value by 148% in the SK-MEL-2 cell line and 127% in the SK-MEL-28 cell line [2].
|
|---|---|
| ln Vivo |
In non-tumor-bearing B6D2F1 mice, intraperitoneal injection of 3,4-dihydroxybenzylamine hydrobromide (1000 mg/kg; 7 days) produces few adverse effects, and the mice are able to tolerate this dose [3]. The effects of intraperitoneal injection of 3,4-dihydroxybenzylamine hydrobromide (200–800 mg/kg; 21 days) vary depending on the dose. At 0 mg/kg and 200 mg/kg, the median life spans are 17, 24.5, and 26, respectively. Days 25 and 29. mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, in that order[3].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: human and mouse melanoma cell lines; non-melanoma cell lines Tested Concentrations: 1 μM-10 mM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibition of melanoma cell line growth. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice with B6D2F1 cells [3]
Doses: 200 mg/kg, 400 mg/kg, 600 mg/kg and 800 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Life span increased by 44%, 200 mg/kg, 400 mg/kg, 600 mg/kg and 800 mg/kg are 46%, 70% and 50% respectively. |
| References |
[1]. FitzGerald GB, et al. 3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymerase.J Invest Dermatol. 1983 Feb;80(2):119-23.
[2]. Prezioso JA1,et al.Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.Pigment Cell Res. 1990 Mar-Apr;3(2):49-54. [3]. Mlchael M. Wick,et al. 3,4-Dihydroxybenzylamine: Antitumor Activity Against A Dopamine Analog B16 Melanoma. |
| Molecular Formula |
C7H10BRNO2
|
|---|---|
| Molecular Weight |
220.0638
|
| Exact Mass |
218.989
|
| CAS # |
16290-26-9
|
| PubChem CID |
13343562
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.309g/cm3
|
| Boiling Point |
333.4ºC at 760mmHg
|
| Melting Point |
184-186 °C(lit.)
|
| Flash Point |
155.5ºC
|
| Vapour Pressure |
1.32E-05mmHg at 25°C
|
| LogP |
2.214
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
108
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Br[H].O([H])C1=C(C([H])=C([H])C(=C1[H])C([H])([H])N([H])[H])O[H]
|
| InChi Key |
BVFZTXFCZAXSHN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO2.BrH/c8-4-5-1-2-6(9)7(10)3-5;/h1-3,9-10H,4,8H2;1H
|
| Chemical Name |
4-(aminomethyl)benzene-1,2-diol;hydrobromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~378.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5442 mL | 22.7211 mL | 45.4422 mL | |
| 5 mM | 0.9088 mL | 4.5442 mL | 9.0884 mL | |
| 10 mM | 0.4544 mL | 2.2721 mL | 4.5442 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
